Category: District of Delaware
-
Qualcomm, Arm each claim victory in architecture licensing standoff; jury awards $2 damages
The two chipmakers have been engaged in a long-running contractual dispute over use of Arm’s processor architecture IP.
-
Disney hit with Delaware complaint from ETRI over video coding SEPs
ETRI claims that Disney was repeatedly contacted by Access Advance to take a (F)RAND license to the VDP pool, which would cover the asserted patents.
-
Janssen wins landmark preliminary injunction in District of Delaware
The U.S. District Court has issued a preliminary injunction against Accord BioPharma and Bio- Thera Solutions over the alleged infringement of 17 of Janssen’s patents related to golimumab, a key ingredient in its drugs used to treat rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and ulcerative colitis.
-
Federal Circuit distinguishes impossibility from indefiniteness, affirms Samsung invalidity win on enablement grounds
The Federal Circuit upheld Samsung’s invalidity win, but shifted the basis from indefiniteness to lack of enablement.
-
Mylan seeks declaratory judgment against Novo Nordisk over newly issued Wegovy patent, aiming to preempt a new Delaware lawsuit
Mylan has asked a Delaware court to declare a newly issued Novo Nordisk Wegovy patent invalid and not infringed, opening a new front in their long-running Hatch-Waxman fight over generic semaglutide.
-
Solar patent wars: GameChange hits back at Nextpower in District of Delaware over solar tracking technology
The battle opens another front in the complex web of patent disputes over solar energy technologies.
-
Part-win for Philips in Delaware 3G patent fight: Quectel infringes one of four asserted patents
A jury in the District of Delaware has said that Quectel’s cellular communication modules infringe only one of two remaining asserted patents from an enforcement campaign Philips started in December 2020. Quectel must pay over $3 million in damages to Philips, the jury has also found.
-
Lupin granted win against Vertex in Delaware over cystic fibrosis drug patents
Lupin’s generic version of Vertex’s cystic fibrosis treatment Kalydeco does not infringe the latter’s patents, Judge Stephanos Bibas of the Third Circuit has ruled.
-
Guardant Health ordered to pay TwinStrand Biosciences and University of Washington $245M in Delaware dispute over DNA sequencing patents
The co-plaintiffs were originally awarded $83.4 million by a District of Delaware jury in November 2023.